SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
705>>Which to take first, the well tolerated drug or the one with the nasty sIRWIN JAMES FRANKEL-5/18/2011
704Exelixis Launches Online Summit Featuring Expert Perspectives on Cancer TreatmenIRWIN JAMES FRANKEL-5/18/2011
703Which to take first, the well tolerated drug or the one with the nasty side efferkrw-5/18/2011
702>>I'm not sure I would look at these two drugs as competitive. RightIRWIN JAMES FRANKEL-5/17/2011
701I'm not sure I would look at these two drugs as competitive. XL-184 for allrkrw-5/17/2011
700Institutional holdings shot up in 1Q: The IH tables are mostly updated. IH incIRWIN JAMES FRANKEL-5/17/2011
699>> I have the impression (from the PRs alone) that Cabo is doing better thIRWIN JAMES FRANKEL-5/17/2011
698YM >>icprecipice It is my understanding that urinary N-telopeptide (uNTx)IRWIN JAMES FRANKEL-5/17/2011
697I have the impression (from the PRs alone) that Cabo is doing better than Xgeva Ian@SI-5/17/2011
696For comparison's sake when the Exel data comes out... FDA Approves First Drrkrw-5/16/2011
695businesswire.com May 13, 2011 04:05 PM Eastern Daylight Time Exelixis AnnounceIRWIN JAMES FRANKEL-5/13/2011
694<reply> and <OT>. Sorry I didn't catch that. It is hard for mekenhott15/9/2011
693by Earnie on YM <<It seemed Dr. Morrissey was very optimistic about the PIRWIN JAMES FRANKEL-5/5/2011
692Earnings call transcript: seekingalpha.com Slide 8 in the presentation is inteIRWIN JAMES FRANKEL-5/4/2011
691Exelixis' CEO Discusses Q1 2011 Results - Earnings Call Transcript seekingNeil H-5/4/2011
690SI jumped 44% to the highest level in the last year. When the share offering waIRWIN JAMES FRANKEL-4/27/2011
689YM by Earnie <<Ernie mentioned his excitement for ovarian cancer, and theIRWIN JAMES FRANKEL-4/22/2011
688YM - i-rat - combining two posts of his Oh I love what I have seen so far. I amIRWIN JAMES FRANKEL-4/21/2011
687YM - i-rat If I was a prostate cancer doc,,, 12 minutes ago I would useIRWIN JAMES FRANKEL-4/20/2011
686YM - i-rat 50,000 incidence bone mets prostate CA,,, 33 minutes ago ThIRWIN JAMES FRANKEL-4/20/2011
685Xgeva info from AMGN’s 1Q11 CC: siliconinvestor.com FWIWDewDiligence_on_SI-4/20/2011
684>>Note there is now another approved drug for MTC, so that might slow downIRWIN JAMES FRANKEL-4/20/2011
683<i>assuming the drug is on market for MTC</i> Note there is now anoBiomaven-4/20/2011
682<abstracts will not be out until May 18> I would assume the abstracts woukenhott-4/20/2011
681I don't have to tell you that it is about the data and to a lesser degree hykenhott-4/20/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News